Zions Bancorporation National Association UT Decreases Stock Position in Medpace Holdings, Inc. $MEDP

Zions Bancorporation National Association UT cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 49.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,487 shares of the company’s stock after selling 1,464 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Medpace were worth $788,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in MEDP. NewEdge Advisors LLC grew its stake in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after acquiring an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after acquiring an additional 3,010 shares during the period. Geneos Wealth Management Inc. raised its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC bought a new stake in Medpace in the 2nd quarter valued at about $296,000. Finally, M&T Bank Corp lifted its holdings in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after purchasing an additional 31 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on MEDP. Robert W. Baird increased their target price on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Barclays set a $600.00 price target on shares of Medpace in a research report on Thursday, July 23rd. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday. Finally, Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $584.18.

Medpace Stock Down 0.6%

Shares of MEDP opened at $578.50 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The stock has a market cap of $16.15 billion, a PE ratio of 33.91, a P/E/G ratio of 2.60 and a beta of 1.15. The business’s 50-day moving average price is $536.23 and its 200-day moving average price is $492.35.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace’s revenue was up 17.2% compared to the same quarter last year. During the same period last year, the business earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Activity

In other Medpace news, CEO August J. Troendle sold 458 shares of the stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $600.39, for a total value of $274,978.62. Following the sale, the chief executive officer directly owned 603,978 shares in the company, valued at $362,622,351.42. This represents a 0.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 67,195 shares of company stock valued at $37,989,998. 20.50% of the stock is owned by company insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.